Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schliemann

Showing results (371-380 of 427) with videos related to

Pageof 43
Sort By:
Journal of Autism and Developmental Disorders|February 28, 2023
Environmental Correlates of Physical Activity and Screen-Time in Youth with Autism Spectrum Disorder: A Seven-Country Observational StudyJustin A Haegele, Fenghua Sun, Chunxiao Li, et al.
The EMBO Journal|November 18, 2024
Towards routine proteome profiling of FFPE tissue: insights from a 1,220-case pan-cancer studyJohanna Tüshaus, Stephan Eckert, Marius Schliemann, et al.
Journal of Cancer Research and Clinical Oncology|March 15, 2023
An overview and a roadmap for artificial intelligence in hematology and oncologyWiebke Rösler, Michael Altenbuchinger, Bettina Baeßler, et al.
Nature Communications|August 4, 2019
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AMLThomas Oellerich, Constanze Schneider, Dominique Thomas, et al.
Leukemia|July 1, 2017
An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemiaL Angenendt, S Reuter, D Kentrup, et al.
Blood Advances|April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapseAndrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Hemasphere|May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLJan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
European Journal of Haematology|November 9, 2017
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclinesEva Lengfelder, Dennis Görlich, Daniel Nowak, et al.
Contact Dermatitis|January 31, 2022
European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCA<sup>A</sup> and the EBS<sup>B</sup> working groups of the ESCD, and the GEIDAC<sup>C</sup>Wolfgang Uter, S Mark Wilkinson, Olivier Aerts, et al.
Pageof 43

Showing results (371-380 of 427) with videos related to

Sort By:
Pageof 43
Journal of Autism and Developmental Disorders|February 28, 2023
Environmental Correlates of Physical Activity and Screen-Time in Youth with Autism Spectrum Disorder: A Seven-Country Observational StudyJustin A Haegele, Fenghua Sun, Chunxiao Li, et al.
The EMBO Journal|November 18, 2024
Towards routine proteome profiling of FFPE tissue: insights from a 1,220-case pan-cancer studyJohanna Tüshaus, Stephan Eckert, Marius Schliemann, et al.
Journal of Cancer Research and Clinical Oncology|March 15, 2023
An overview and a roadmap for artificial intelligence in hematology and oncologyWiebke Rösler, Michael Altenbuchinger, Bettina Baeßler, et al.
Nature Communications|August 4, 2019
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AMLThomas Oellerich, Constanze Schneider, Dominique Thomas, et al.
Leukemia|July 1, 2017
An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemiaL Angenendt, S Reuter, D Kentrup, et al.
Blood Advances|April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapseAndrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Hemasphere|May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLJan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
European Journal of Haematology|November 9, 2017
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclinesEva Lengfelder, Dennis Görlich, Daniel Nowak, et al.
Contact Dermatitis|January 31, 2022
European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCA<sup>A</sup> and the EBS<sup>B</sup> working groups of the ESCD, and the GEIDAC<sup>C</sup>Wolfgang Uter, S Mark Wilkinson, Olivier Aerts, et al.
Pageof 43